Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade N McGranahan, AJS Furness, R Rosenthal, S Ramskov, R Lyngaa, ... Science 351 (6280), 1463-1469, 2016 | 3062 | 2016 |
ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells DW Lee, BD Santomasso, FL Locke, A Ghobadi, CJ Turtle, JN Brudno, ... Biology of blood and marrow transplantation 25 (4), 625-638, 2019 | 2402 | 2019 |
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution C Abbosh, NJ Birkbak, GA Wilson, M Jamal-Hanjani, T Constantin, ... Nature 545 (7655), 446-451, 2017 | 1761 | 2017 |
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma TR Simpson, F Li, W Montalvo-Ortiz, MA Sepulveda, K Bergerhoff, F Arce, ... Journal of Experimental Medicine 210 (9), 1695-1710, 2013 | 1623 | 2013 |
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies KS Peggs, SA Quezada, CA Chambers, AJ Korman, JP Allison Journal of Experimental Medicine 206 (8), 1717-1725, 2009 | 1117 | 2009 |
Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts SA Quezada, TR Simpson, KS Peggs, T Merghoub, J Vider, X Fan, ... Journal of Experimental Medicine 207 (3), 637-650, 2010 | 1016 | 2010 |
Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells W Qasim, H Zhan, S Samarasinghe, S Adams, P Amrolia, S Stafford, ... Science translational medicine 9 (374), eaaj2013, 2017 | 989 | 2017 |
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells SA Quezada, KS Peggs, MA Curran, JP Allison The Journal of clinical investigation 116 (7), 1935-1945, 2006 | 806 | 2006 |
Checkpoint blockade in cancer immunotherapy AJ Korman, KS Peggs, JP Allison Advances in immunology 90, 297-339, 2006 | 747 | 2006 |
Multiplex genome-edited T-cell manufacturing platform for “off-the-shelf” adoptive T-cell immunotherapies L Poirot, B Philip, C Schiffer-Mannioui, D Le Clerre, I Chion-Sotinel, ... Cancer research 75 (18), 3853-3864, 2015 | 646 | 2015 |
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation PD Kottaridis, DW Milligan, R Chopra, RK Chakraverty, S Chakrabarti, ... Blood, The Journal of the American Society of Hematology 96 (7), 2419-2425, 2000 | 609 | 2000 |
Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines KS Peggs, S Verfuerth, A Pizzey, N Khan, M Guiver, PA Moss, ... The Lancet 362 (9393), 1375-1377, 2003 | 592 | 2003 |
Principles and use of anti-CTLA4 antibody in human cancer immunotherapy KS Peggs, SA Quezada, AJ Korman, JP Allison Current opinion in immunology 18 (2), 206-213, 2006 | 581 | 2006 |
Fc effector function contributes to the activity of human anti-CTLA-4 antibodies FA Vargas, AJS Furness, K Litchfield, K Joshi, R Rosenthal, E Ghorani, ... Cancer cell 33 (4), 649-663. e4, 2018 | 559 | 2018 |
Epitope landscape in breast and colorectal cancer NH Segal, DW Parsons, KS Peggs, V Velculescu, KW Kinzler, ... Cancer research 68 (3), 889-892, 2008 | 489 | 2008 |
A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy B Philip, E Kokalaki, L Mekkaoui, S Thomas, K Straathof, B Flutter, ... Blood, The Journal of the American Society of Hematology 124 (8), 1277-1287, 2014 | 448 | 2014 |
High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution S Chakrabarti, S Mackinnon, R Chopra, PD Kottaridis, K Peggs, ... Blood, The Journal of the American Society of Hematology 99 (12), 4357-4363, 2002 | 431 | 2002 |
Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors FA Vargas, AJS Furness, I Solomon, K Joshi, L Mekkaoui, MH Lesko, ... Immunity 46 (4), 577-586, 2017 | 428 | 2017 |
Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen R Chakraverty, K Peggs, R Chopra, DW Milligan, PD Kottaridis, ... Blood, The Journal of the American Society of Hematology 99 (3), 1071-1078, 2002 | 402 | 2002 |
Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation KS Peggs, A Hunter, R Chopra, A Parker, P Mahendra, D Milligan, ... The Lancet 365 (9475), 1934-1941, 2005 | 349 | 2005 |